Alnylam Pharmaceuticals, Inc.ALNY
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $4.29B, growing 82.6% year-over-year. TTM net income stood at $577.22M (314.0% growth). Quarterly EBITDA was $268.64M and operating income was $268.64M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze ALNY growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters